EcoDrugPlus

Akt Serine/threonine Kinase 2

Ensembl ID : ENSCHYG00000027151
Gene Symbol: AKT2
1 Cross references
257 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSCHYG00000016172
Gene Symbol: AKT3
1 Cross references
201 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSCHYG00000014459
Gene Symbol: ALK
1 Cross references
195 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSCHYG00000010161
Gene Symbol: ABCC1
1 Cross references
203 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSCHYG00000013838
Gene Symbol: ABCC8
1 Cross references
245 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSCHYG00000016336
Gene Symbol: ABCC9
1 Cross references
233 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSCHYG00000005682
Gene Symbol: ATP4A
1 Cross references
183 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSCHYG00000015990
Gene Symbol: ATP4B
1 Cross references
171 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSCHYG00000013765
Gene Symbol: ATP1A1
1 Cross references
328 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 3

Ensembl ID : ENSCHYG00000000627
Gene Symbol: ATP1A3
1 Cross references
134 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 4

Ensembl ID : ENSCHYG00000012705
Gene Symbol: ATP1A4
1 Cross references
571 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSCHYG00000014016
Gene Symbol: ATP1B1
1 Cross references
288 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).